ACADIA PHARMACEUTICALS INC. Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent
ACADIA PHARMACEUTICALS INC. (ACAD) reported Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent of 60.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Defined Contribution Plan
us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent · last filed 2026-02-26
- ACADIA PHARMACEUTICALS INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2025 was 60.00%, a 0.00% change from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2024 was 60.00%, a 0.00% change from fiscal 2023.
- ACADIA PHARMACEUTICALS INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2023 was 60.00%, a 0.00% change from fiscal 2022.
- ACADIA PHARMACEUTICALS INC. defined contribution plan, maximum annual contributions per employee, percent for fiscal 2022 was 60.00%, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent 12 month |
|---|---|
| 2025-12-31 | 60.00% 10-K · filed 2026-02-26 |
| 2024-12-31 | 60.00% 10-K · filed 2025-02-27 |
| 2023-12-31 | 60.00% 10-K · filed 2024-02-28 |
| 2022-12-31 | 60.00% 10-K · filed 2023-02-28 |
| 2021-12-31 | 60.00% 10-K · filed 2022-03-01 |
| 2020-12-31 | 60.00% 10-K · filed 2021-02-25 |
| 2019-12-31 | 60.00% 10-K · filed 2020-02-27 |
| 2018-12-31 | 60.00% 10-K · filed 2019-02-27 |
| 2017-12-31 | 60.00% 10-K · filed 2018-02-27 |
| 2016-12-31 | 60.00% 10-K · filed 2017-02-28 |
| 2015-12-31 | 60.00% 10-K · filed 2016-02-29 |
| 2014-12-31 | 60.00% 10-K · filed 2015-02-26 |
| 2013-12-31 | 60.00% 10-K · filed 2014-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |